JPRN-UMIN000027219已完成2 期
Phase II trial of Transcatheter arterial micro-embolization for refractory chronic hip pain: Multicenter Study (REACH study) - hip TAME: JMIS-1603 (REACH study)
Miyakojima IGRT clinic0 个研究点目标入组 20 人开始时间: 2017年5月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Surgical candidate 2.Patients with severe infection, rheumatoid arthritis, or mental disorder 3.Patients with uncontrollable diabetic mellitus 4.Pain due to spine pathology 5.Patients with osteonecrosis with magnetic resonance imaging (MRI) 6.Patients without possibility of going to hospital and follow up for 6 months. 7.Patient who was decided not to be appropriate for this trial by physician
研究者
相似试验
已完成
2 期
Phase II trial of Transcatheter arterial micro-embolization for refractory chronic knee pain: Multicenter Study (PATRICK study)chronic knee pain refractory to non-surgical management due to mild osteoarthritis or after artificial joint replacementJPRN-UMIN000023442Miyakojima IGRT clinic50
已完成
2 期
Phase II trial of transcatheter arterial micro-embolization using imipenem/cilastatin sodium for refractory pain from tendinopathy and enthesopathy: Multicenter Study (INSTEP study)JPRN-UMIN000024385Miyakojima IGRT clinic20
招募中
1 期
Effectiveness of Transcatheter arterial micro-emblization for nighttime shoulder painighttime shoulder pain refractory to traditional managementsJPRN-UMIN000017524Edogawa musculoskeletal intervention study group50
已完成
2 期
Effectiveness of Transcatheter arterial micro-emblization for nighttime shoulder pain : Multicenter Studynighttime shoulder pain refractory to non-surgical managementJPRN-UMIN000021238Edogawa Hospital100
已完成
1 期
Phase 1/2 trial of TAME(:Transcatheter arterial micro embolization) for chronic musculoskeletal pain refractory to non-surgical managementMusculoskeletal chronic pain refractory to non-surgical managementJPRN-UMIN000014591Edogawa Musculoskeletal Intervention Study Group33